Alphabet's Verily unit is seeking U.S. Environmental Protection Agency approval to release millions of sterilized male mosquitoes in Florida and California [1, 3].
This initiative aims to curb the spread of mosquito-borne illnesses, including dengue and Zika, by reducing the overall population of disease-carrying insects [1, 2, 3]. By introducing sterile males into the wild, the company intends to disrupt the breeding cycle, effectively preventing the birth of new larvae.
Verily is requesting permission to release up to 32 million mosquitoes [1]. However, other reports indicate the number of lab-bred insects could reach 64 million [2]. The project focuses on the use of Wolbachia-infected male mosquitoes [4]. Wolbachia is a naturally occurring bacterium that, when introduced into male mosquitoes, renders them sterile or prevents offspring from surviving.
The target areas for these releases are specifically located in Florida and California [3]. These states face ongoing challenges with invasive mosquito species that transmit tropical diseases. The process relies on the fact that only female mosquitoes bite humans; the released males do not pose a direct disease risk to the public [4].
Approval from the EPA remains pending as of early June 2026 [4, 5]. The regulatory process involves assessing the environmental impact of introducing large quantities of lab-bred insects into local ecosystems. Verily has not provided a specific timeline for the start of the releases, pending the federal decision [5].
This method of population suppression is part of a broader scientific effort to replace chemical pesticides with biological controls. By targeting the reproductive capability of the insects, the company hopes to achieve a sustainable reduction in the local mosquito population without altering the genetic makeup of the wild species permanently [1, 4].
“Alphabet's Verily unit is seeking U.S. Environmental Protection Agency approval to release millions of sterilised male mosquitoes.”
The use of Wolbachia-infected insects represents a shift toward biological population control to manage public health crises. If the EPA grants approval, this deployment would mark a significant scaling of Alphabet's life-sciences ambitions, moving from laboratory research to large-scale environmental intervention in two of the most populous U.S. states.
